Oct 30 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX :
* AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION GRANTED SCENESSE RIGHT TO BE FILED UNDER PRIORITY REGISTRATION PROCESS
* CLINUVEL INTENDS TO SUBMIT SCIENTIFIC DOSSIER IN Q1 2020
* SCENESSE TO TREAT PATIENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA (EPP) IN AUSTRALIA